Table 2.
The endotoxin-induced cells count response in sputum before and after a treatment with control, oralsteroids and anti-TNF
| Parameters | Total | Control | PDN | p value ‡ | Anti-TNF | p value ‡ |
|---|---|---|---|---|---|---|
| .(1) | .(2) | (1) vs (2) | .(3) | (1) vs (3) | ||
| n | 30 | 9 | 10 | 10 | ||
| Total viable cells (cells/μL) | ||||||
| Before LPS | 1811 (1191–2748) | 2716 (1132–6741) | 1820 (805–4111) | 1000 (607–1648) | ||
| After LPS | 4188 2754–6368) | 4570 (2004–10399) | 4447 (2060–9571) | 2884 (1352–6152) | ||
| After LPS + treatment | 6039 1883–19408) | 3963 (2004–7834) | NS | 1261 (591–2691) | 0.052 | |
| p value † | < 0.0001 | |||||
| Neutrophils (cells/μL) | ||||||
| Before | 520 (299)906) | 789 (229–2710) | 561 (207–1517) | 244 (120–498) | ||
| After LPS | 1954 (1135–3357) | 1795 (560–5768) | 2387 (1019–5598) | 1321 (443–3935) | ||
| After LPS + treatment | 2594 (614–10990) | 2313 (1084–5284) | NS | 247 (68–906) | < 0.02 | |
| p value † | p <0.0001 | |||||
| Macrophages (cells/μL) | ||||||
| Before | 993 (681–1449) | 1438 (692–2985) | 914 (395–2113) | 656 (396–1089) | ||
| After LPS | 1618 (1138–2296) | 1786 (939–3396) | 1644 (807–3350) | 1180 (661–2089) | ||
| After LPS + treatment | 1892 (647–5508) | 1185 (528–2654) | NS | 873 (457–1660) | NS | |
| p value † | p <0.001 | |||||
| Lymphocytes (cells/μL) | ||||||
| Before | 39 (23–65) | 65 (29–147) | 33 (12–91) | 21 (8–54) | ||
| After LPS | 119 (71–201) | 155 (64–378) | 125 (54–299) | 67 (20–219) | ||
| After LPS + treatment | 198 (42–929) | 54(18–156) | NS | 22 (3–159) | NS | |
| p value † | p <0.0001 | |||||
| Neutrophils (%) | ||||||
| Before | 35 .0 (26.9-43.1) | 36.8 (18.3-55.3) | 37.3 19.0-55.3) | 28.2 (18.2-38.1) | ||
| After LPS | 52.4 (44.6-60.3) | 48.4 (27.1-69.8) | 55.9 (44.0-67.8) | 51.3 (36.8-65.8) | ||
| After LPS + treatment | 49.6 (28.2-70.9) | 63.8 (49.8-77.8) | NS | 26.2 (14.1-38.2) | < 0.002 | |
| p value † | p <0.0001 | |||||
| Macrophages (%) | ||||||
| Before | 60.7 (52.2-62.2) | 58.6 (39.8-77.5) | 59.5 (39.5-79.5) | 67.1 (57.2-77.0) | ||
| After LPS | 43.8 (35.9-51.8) | 47.8 (26.2-69.3) | 40.8 (28.7-52.8) | 44.7 (29.8-59.6) | ||
| After LPS + treatment | 46.9 (24.5-69.3) | 34.6 23.4-48.8) | < 0.002 | 71.3 (58.4-84.1) | NS | |
| p value † | p <0.0001 | |||||
| Lymphocytes (%) | ||||||
| Before | 2.7 (1.5-3.9) | 2.1 (0.8-3.4) | 2.7 (0.6-4.8) | 3.3 (0.1-6.3) | ||
| After LPS | 3.0 (2.3-3.6) | 3.1 (1.6-4.6) | 3.1 (2.4-4.1) | 2.8 (1.4-4.1) | ||
| After LPS + treatment | 2.9 (0.9-5.0) | 1.3 (0.6-2.0) | NS | 1.5 (0.3-3.2) | 0.052 | |
| p value † | NS | |||||
The % and absolute values are expressed as arithmetic or geometric means, respectively (95% Confidence Interval). PDN, methylprednisolone.
‡Unpaired t-tests were used to compare the changes among control (1) with the changes after prednisolone (2) or anti-TNF (3).
†Paired t-test to compare the cell counts before and after LPS, among the whole population.